Compare Stocks: CING, IKT, EYPT, and VNDA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CING Cingulate	$4.89	$5.12	$3.16 ▼ $11.89	$71.10M	-0.88	91,411 shs	27,812 shs
EYPT Eyepoint Pharmaceuticals	$3.40	$5.97	$3.05 ▼ $19.11	$293.11M	1.67	3.44 million shs	1.94 million shs
IKT Inhibikase Therapeutics	$1.97	$2.30	$1.33 ▼ $2.61	$274.89M	0.89	607,851 shs	435,034 shs
VNDA Vanda Pharmaceuticals	$4.57	$5.13	$4.27 ▼ $9.94	$276.30M	0.69	1.13 million shs	639,800 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CING Cingulate	0.00%	+2.73%	-2.59%	+4.49%	+18.98%
EYPT Eyepoint Pharmaceuticals	0.00%	+4.62%	-19.62%	-76.19%	-74.94%
IKT Inhibikase Therapeutics	0.00%	-1.50%	-15.81%	+0.51%	+22.36%
VNDA Vanda Pharmaceuticals	0.00%	-1.30%	-10.22%	-23.83%	-13.94%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CING Cingulate	$4.89	$5.12	$3.16 ▼ $11.89	$71.10M	-0.88	91,411 shs	27,812 shs
EYPT Eyepoint Pharmaceuticals	$3.40	$5.97	$3.05 ▼ $19.11	$293.11M	1.67	3.44 million shs	1.94 million shs
IKT Inhibikase Therapeutics	$1.97	$2.30	$1.33 ▼ $2.61	$274.89M	0.89	607,851 shs	435,034 shs
VNDA Vanda Pharmaceuticals	$4.57	$5.13	$4.27 ▼ $9.94	$276.30M	0.69	1.13 million shs	639,800 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CING Cingulate	0.00%	+2.73%	-2.59%	+4.49%	+18.98%
EYPT Eyepoint Pharmaceuticals	0.00%	+4.62%	-19.62%	-76.19%	-74.94%
IKT Inhibikase Therapeutics	0.00%	-1.50%	-15.81%	+0.51%	+22.36%
VNDA Vanda Pharmaceuticals	0.00%	-1.30%	-10.22%	-23.83%	-13.94%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CING Cingulate	2.50	Moderate Buy	$27.00	452.15% Upside
EYPT Eyepoint Pharmaceuticals	2.27	Hold	$25.70	655.88% Upside
IKT Inhibikase Therapeutics	3.00	Buy	$5.40	174.11% Upside
VNDA Vanda Pharmaceuticals	2.44	Hold	$13.08	186.29% Upside

Current Analyst Ratings Breakdown

Latest CING, IKT, EYPT, and VNDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/6/2026	VNDA Vanda Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
10/5/2026	VNDA Vanda Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
10/2/2026	CING Cingulate	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/23/2026	VNDA Vanda Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$10.00
9/16/2026	CING Cingulate	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/2/2026	EYPT Eyepoint Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$20.00 ➝ $4.00
9/1/2026	EYPT Eyepoint Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/23/2026	CING Cingulate	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$10.00 ➝ $9.00
8/18/2026	CING Cingulate	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/18/2026	EYPT Eyepoint Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$17.00
8/18/2026	EYPT Eyepoint Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$5.00

(Data available from 10/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CING Cingulate	N/A	N/A	N/A	N/A	$0.31 per share	N/A
EYPT Eyepoint Pharmaceuticals	$31.37M	9.34	N/A	N/A	$3.70 per share	0.92
IKT Inhibikase Therapeutics	$260K	1,057.28	N/A	N/A	$2.30 per share	0.86
VNDA Vanda Pharmaceuticals	$216.10M	1.28	N/A	N/A	$5.54 per share	0.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CING Cingulate	-$22.45M	-$3.59	N/A	N/A	N/A	N/A	-238.40%	-128.67%	11/12/2026 (Estimated)
EYPT Eyepoint Pharmaceuticals	-$231.96M	-$3.74	N/A	N/A	N/A	-10,994.73%	-135.81%	-108.35%	11/4/2026 (Estimated)
IKT Inhibikase Therapeutics	-$48.26M	-$0.43	N/A	N/A	N/A	N/A	-42.80%	-40.58%	N/A
VNDA Vanda Pharmaceuticals	-$220.47M	-$4.63	N/A	N/A	N/A	-127.41%	-49.81%	-33.29%	11/4/2026 (Estimated)

Latest CING, IKT, EYPT, and VNDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	EYPT Eyepoint Pharmaceuticals	-$0.9052	N/A	N/A	N/A	$0.23 million	N/A
11/4/2026	Q3 2026	VNDA Vanda Pharmaceuticals	-$0.72	N/A	N/A	N/A	$69.20 million	N/A
8/13/2026	Q2 2026	CING Cingulate	-$0.63	-$0.45	+$0.18	-$0.45	$0.17 million	N/A
8/11/2026	Q2 2026	IKT Inhibikase Therapeutics	-$0.09	-$0.11	-$0.02	-$0.11	N/A	N/A
8/5/2026	Q2 2026	EYPT Eyepoint Pharmaceuticals	-$1.01	-$1.09	-$0.08	-$0.2720	$0.45 million	$0.51 million
8/5/2026	Q2 2026	VNDA Vanda Pharmaceuticals	-$0.5825	-$1.04	-$0.4575	-$1.04	$61.93 million	$50.53 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CING Cingulate	N/A	N/A	N/A	N/A	N/A
EYPT Eyepoint Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
VNDA Vanda Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CING Cingulate	N/A	3.50	3.50
EYPT Eyepoint Pharmaceuticals	N/A	4.50	4.46
IKT Inhibikase Therapeutics	N/A	15.82	15.82
VNDA Vanda Pharmaceuticals	0.01	1.61	1.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CING Cingulate	41.31%
EYPT Eyepoint Pharmaceuticals	99.41%
IKT Inhibikase Therapeutics	3.81%
VNDA Vanda Pharmaceuticals	88.14%

Insider Ownership

Company	Insider Ownership
CING Cingulate	5.30%
EYPT Eyepoint Pharmaceuticals	5.13%
IKT Inhibikase Therapeutics	7.10%
VNDA Vanda Pharmaceuticals	10.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CING Cingulate	14	14.54 million	13.77 million	Not Optionable
EYPT Eyepoint Pharmaceuticals	214	86.21 million	81.79 million	Optionable
IKT Inhibikase Therapeutics	35	139.54 million	129.63 million	N/A
VNDA Vanda Pharmaceuticals	533	60.46 million	53.99 million	Optionable

CING, IKT, EYPT, and VNDA Headlines

Recent News About These Companies

Vanda’s Tasimelteon Study Completion: What Sleep Trial Progress Means for VNDA Investors

October 9 at 12:31 PM | tipranks.com

Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Bumped Down to "Strong Sell" by Zacks Research

October 8, 2026 | americanbankingnews.com

Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Rating Lowered by Zacks Research

October 8, 2026 | marketbeat.com

Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Rating Reaffirmed as Buy by HC Wainwright

October 5, 2026 | marketbeat.com

Vanda Pharmaceuticals: Buy Rating Reaffirmed as HETLIOZ Phase 3 Success in DSWPD Supports sNDA; $20 Price Target Maintained

October 5, 2026 | tipranks.com

Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting

October 2, 2026 | prnewswire.com

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Average Recommendation of "Moderate Buy" from Brokerages

October 2, 2026 | americanbankingnews.com

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Consensus Rating of "Moderate Buy" from Analysts

October 2, 2026 | marketbeat.com

Vanda: 'Hold' On Hetlioz Trial Win, But Several Risk Factors Remain For It

October 1, 2026 | seekingalpha.com

VNDA Stock Fades After Hetlioz Sleep-Trial Win — Here’s Why

September 30, 2026 | msn.com

Vanda's HETLIOZ Meets Phase 3 Goal In Delayed Sleep-Wake Phase Disorder; Stock Up

September 30, 2026 | rttnews.com

Vanda Reports Positive Phase 3 Results For HETLIOZ In Delayed Sleep-Wake Phase Disorder; Stock Up

September 30, 2026 | rttnews.com

Vanda posts late-stage trial win for HETLIOZ in DSWPD, setting up another label expansion

September 30, 2026 | msn.com

Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder

September 29, 2026 | prnewswire.com

Vanda's Year-End Catalysts: Three Phase 3 Readouts And An FDA Decision Ahead

September 28, 2026 | rttnews.com

Vanda Pharmaceuticals Inc. $VNDA Stock Purchased by State Street Corp

September 26, 2026 | marketbeat.com

Oppenheimer initiates coverage of Vanda Pharmaceuticals with an outperform rating

September 23, 2026 | msn.com

Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences

September 2, 2026 | prnewswire.com

Vanda Pharmaceuticals Inc. (VNDA)

August 25, 2026 | finance.yahoo.com

Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission

August 24, 2026 | prnewswire.com

NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.

August 22, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CING, IKT, EYPT, and VNDA Company Descriptions

Cingulate NASDAQ:CING

$4.89 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$4.93 +0.04 (+0.82%)

As of 10/9/2026 07:39 PM Eastern

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Eyepoint Pharmaceuticals NASDAQ:EYPT

$3.40 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$3.41 +0.01 (+0.18%)

As of 10/9/2026 07:30 PM Eastern

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Inhibikase Therapeutics NASDAQ:IKT

$1.97 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.96 0.00 (-0.25%)

As of 10/9/2026 07:30 PM Eastern

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Vanda Pharmaceuticals NASDAQ:VNDA

$4.57 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$4.53 -0.04 (-0.92%)

As of 10/9/2026 07:54 PM Eastern

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CING, IKT, EYPT, and VNDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CING, IKT, EYPT, and VNDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CING, IKT, EYPT, and VNDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CING, IKT, EYPT, and VNDA Company Descriptions

Cingulate NASDAQ:CING

Eyepoint Pharmaceuticals NASDAQ:EYPT

Inhibikase Therapeutics NASDAQ:IKT

Vanda Pharmaceuticals NASDAQ:VNDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CING, IKT, EYPT, and VNDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CING, IKT, EYPT, and VNDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CING, IKT, EYPT, and VNDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CING, IKT, EYPT, and VNDA Company Descriptions

Cingulate NASDAQ:CING

Eyepoint Pharmaceuticals NASDAQ:EYPT

Inhibikase Therapeutics NASDAQ:IKT

Vanda Pharmaceuticals NASDAQ:VNDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools